StreetAlpha.app
Home › Stocks › IONS

Ionis Pharmaceuticals Inc (IONS)

Healthcare
$26.96
▼ −3.75%
LAST CLOSE · NOV 17

Ionis Pharmaceuticals develops and sells medicines that act on RNA to treat serious diseases, mainly rare genetic conditions. It last closed at $26.96 on Nov 17, down 3.75% on the day. The average 12-month price target from 14 analysts is $69.79 (+158.8% from the last close), with a high of $88.00 and a low of $41.00. Analyst consensus is Strong Buy, based on the latest ratings from 14 firms (13 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in IONS, 100% of them bullish and 0% bearish. In the past 30 days there were 8 dark pool prints totaling $10.3M, the largest $2.2M.

AI Auto Pilots
Is IONS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$960.1M
−0.7% vs a year ago
Net income
−$546.5M
−56.9% margin
EPS (diluted)
−$3.35
Free cash flow
−$616.3M
−64.2% margin
Valuation
Market cap
$4.5B
166.5M shares
P/E
–
No P/E while losing money
Price to sales
4.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$296.3M
At Sep 30
Shareholder equity
$393.6M
Shares outstanding
166.5M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $810.5M$810.5MFY2021FY2022: $587.4M$587.4MFY2022FY2023: $787.6M$787.6MFY2023FY2024: $705.1M$705.1MFY2024FY2025: $943.7M$943.7MFY2025

From IONS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 14 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
14firms
13 Buy1 Hold0 Sell
Each firm's latest rating on IONS in the past 90 days
Average 12-month target
$69.79
▲ 158.8% upside

Based on 14 analysts who set a price target on IONS in the past 90 days. The average target is $69.79, with a high of $88.00 and a low of $41.00, compared with the last close of $26.96.

$22$46$69$93PAST 16 TRADING DAYS12-MONTH TARGETSHIGH $88AVG $69.79LOW $41Jun 10LAST CLOSE+12 MO$22$46$69$93PAST 16 DAYSTARGETSHIGH $88AVG $69.79LOW $41Jun 10LAST CLOSE+12 MO
Highest target$88.00
Average target$69.79
Lowest target$41.00
Latest rating changes
Goldman SachsTarget lowered
Nov 10Hold$56 → $41
Morgan StanleyTarget lowered
Nov 10Buy$104 → $75
TD CowenMaintained
Nov 10Buy$53
OppenheimerMaintained
Nov 10Buy$70
RBC CapitalTarget lowered
Nov 10Buy$85 → $60
DateFirmActionRatingPrice target
Nov 10Goldman SachsTarget loweredHold$56 → $41
Nov 10Morgan StanleyTarget loweredBuy$104 → $75
Nov 10TD CowenMaintainedBuy$53
Nov 10OppenheimerMaintainedBuy$70
Nov 10RBC CapitalTarget loweredBuy$85 → $60
Loading…

Technical Analysis

IONS · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 39% below its 20 day and 58% below its 50 day average. It is 137% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the 52 week low at $26.55, and the nearest resistance the Pivot at $27.20.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.3%/day
Key levels
$86.7452 week high+221.7%
$63.94200 day average+137.2%
$51.60100 day average+91.4%
$45.72Swing high (Oct 9)+69.6%
$42.4650 day average+57.5%
$37.5120 day average+39.1%
$27.85Pivot R1+3.3%
$27.20Pivot+0.9%
$26.96Last close
$26.5552 week low−1.5%
$26.31Pivot S1−2.4%
Indicators
RSI (14)21.70Oversold below 30Oversold
MACD-4.78Below its signal lineBearish
Stochastic5.3Near the bottom of its rangeOversold
ADX (14)46.2Strong downtrend
Williams %R-97.9Oversold below −80, overbought above −20Oversold
CCI (20)-109.6Oversold below −100, overbought above 100Oversold
Rate of change−33.3%Change over 10 sessionsBearish
ATR (14)$2.23Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IONS

What happened before

See how IONS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IONS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IONS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Oct 13 – Oct 13
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
8
Notional
$10.3M
Largest print
$2.2M
Loading…

IONS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●241 buying vs 275 selling
  • ▼Held by funds -9.0 pts
  • ▼Funds holding -54
  • ▲Superinvestors: 4 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding472526−10.3%
In funds' top 10710−30.0%
Held by funds111.3%120.3%−9.0 pts
New / increased66 / 17568 / 203−11.1%
Reduced / sold out159 / 116164 / 50+28.5%
Put/call ratio1.570.40+292.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IONS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IONS is in one of them and how their past IONS trades turned out.

IONS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IONS in an article yet. Here's the latest on the wider market.

IONS Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Apr 17
Who traded IONS · since 2016
Latest 5 filings of 6
$1K – $15KTraded Mar 6, 2023Filed Apr 17, 2023
$1K – $15KTraded Mar 14, 2023Filed Apr 7, 2023
$1K – $15KTraded Dec 6, 2022Filed Jan 3, 2023
$1K – $15KTraded Jun 24, 2019Filed Apr 27, 2020
$1K – $15KTraded May 8, 2019Filed Apr 27, 2020
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KMar 6, 2023Apr 17, 202342 d
Ro KhannaD · CASell$1K – $15KMar 14, 2023Apr 7, 202324 d
Ro KhannaD · CABuy$1K – $15KDec 6, 2022Jan 3, 202328 d
Donna ShalalaD · FLSell$1K – $15KJun 24, 2019Apr 27, 2020308 d
Donna ShalalaD · FLBuy$1K – $15KMay 8, 2019Apr 27, 2020355 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California, that develops and sells medicines for serious diseases. Its products act on RNA, the molecule that carries genetic instructions, to lower the production of specific proteins in the body. Its marketed medicines treat conditions such as familial chylomicronemia syndrome, hereditary angioedema, and spinal muscular atrophy. Patients receive these medicines through the company's own sales efforts and through partners such as Biogen and AstraZeneca.

Headquarters
Carlsbad, CA